Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Pugh, Siân; Thiébaut, Raphaële; Bridgewater, John; Grisoni, Marie-Lise; Moutasim, Karwan; Rousseau, Francis; Thomas, Gareth J; Griffiths, Gareth; Liebaert, François; Primrose, John; Laurent-Puig, Pierre

Pugh, Siân; Thiébaut, Raphaële; Bridgewater, John; Grisoni, Marie-Lise; Moutasim, Karwan; Rousseau, Francis; Thomas, Gareth J; Griffiths, Gareth; Liebaert, François; Primrose, John; Laurent-Puig, Pierre.

Afiliação

Pugh S; University Surgery, Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Thiébaut R; IntegraGen SA, Evry, France.
Bridgewater J; UCL Cancer Institute, London, United Kingdom.
Grisoni ML; IntegraGen SA, Evry, France.
Moutasim K; Cancer Sciences Division, University of Southampton, Southampton, United Kingdom.
Rousseau F; IntegraGen SA, Evry, France.
Thomas GJ; Cancer Sciences Division, University of Southampton, Southampton, United Kingdom.
Griffiths G; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
Liebaert F; IntegraGen SA, Evry, France.
Primrose J; University Surgery, Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Laurent-Puig P; UMR-S1147, University Paris Descartes, Paris, France.

Oncotarget ; 8(55): 93856-93866, 2017 Nov 07.

Article em En | MEDLINE | ID: mdl-29212194

Palavras-chave

anti-EGFR; biomarker; cetuximab; metastatic colorectal cancer; miR-31-3p

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google